Global Glucose Monitoring Devices Market to Reach $19.2 Billion by 2030
The global market for Glucose Monitoring Devices estimated at US$13.1 Billion in the year 2022, is projected to reach a revised size of US$19.2 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2022-2030. Self-Monitoring Devices, one of the segments analyzed in the report, is projected to record 4% CAGR and reach US$11.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Continuous Blood Glucose Monitoring Devices segment is readjusted to a revised 6.2% CAGR for the next 8-year period.The U.S. Market is Estimated at $3.6 Billion, While China is Forecast to Grow at 8% CAGR
The Glucose Monitoring Devices market in the U.S. is estimated at US$3.6 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$4.1 Billion by the year 2030 trailing a CAGR of 8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.6% and 5.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.Select Competitors (Total 32 Featured) -
- Abbott Diabetes Care, Inc.
- ACON Laboratories, Inc.
- AgaMatrix, Inc.
- Alive Technologies Pty. Ltd.
- ARKRAY, Inc.
- Ascensia Diabetes Care Holdings AG
- B. Braun Melsungen AG
- Beurer GmbH
- Dexcom, Inc.
- GlySens Inc.
- LifeScan, Inc.
- Medtronic plc
- Nova Biomedical Corporation
- Omron Healthcare Co., Ltd.
- Roche Diagnostics
- Senseonics Holdings, Inc.
- Terumo Corporation
- Trividia Health, Inc.
- Ypsomed Holding AG
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Diabetes Care, Inc.
- ACON Laboratories, Inc.
- AgaMatrix, Inc.
- Alive Technologies Pty. Ltd.
- ARKRAY, Inc.
- Ascensia Diabetes Care Holdings AG
- B. Braun Melsungen AG
- Beurer GmbH
- Dexcom, Inc.
- GlySens Inc.
- LifeScan, Inc.
- Medtronic plc
- Nova Biomedical Corporation
- Omron Healthcare Co., Ltd.
- Roche Diagnostics
- Senseonics Holdings, Inc.
- Terumo Corporation
- Trividia Health, Inc.
- Ypsomed Holding AG
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 268 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 13.1 Billion |
Forecasted Market Value ( USD | $ 19.2 Billion |
Compound Annual Growth Rate | 4.9% |
Regions Covered | Global |